Macrophage activation in exacerbated COPD with and without community-acquired pneumonia
Macrophage activation in exacerbated COPD with and without community-acquired pneumonia
复制标题
DOI：
10.1183/09031936.00118909
复制
发表时间：
2010-08-01
影响因子：
24.3
通讯作者：
Torres, A.
中科院分区：
文献类型：
--
作者：
Gutierrez, P.;Closae, D.;Torres, A.
在大量无反应的社区获得性肺炎（CAP）患者中，慢性阻塞性肺疾病（COPD）被观察到是对初始抗生素无反应的保护因素。这一有趣的事实可能与炎症细胞表型的变化有关，特别是与巨噬细胞经典- m1或替代- m2激活的诱导有关，从而导致不同的炎症谱。我们评估了COPD急性加重（AECOPD）、CAP和COPD+CAP患者的痰液对巨噬细胞表型变化的影响。将分化为巨噬细胞的人THP1细胞与AECOPD、CAP或COPD+CAP患者的痰培养，检测肿瘤坏死因子- α、白细胞介素-6、甘露糖受体和精氨酸酶的表达，评估巨噬细胞获得的表型。我们发现CAP患者的痰诱导M1表型，而AECOPD患者的痰诱导m2样表型。CAP+COPD患者的痰没有明确的M1或M2表型。这些结果表明，肺内微环境调节巨噬细胞的激活，导致AECOPD、CAP和COPD+CAP患者出现不同的表型。这种不同类型的激活诱导不同的炎症反应，并可能涉及COPD和CAP同时存在时观察到的不同结果。
In large series of nonresponding community-acquired pneumonia (CAP) patients, chronic obstructive pulmonary disease (COPD) was observed to be a protective factor for nonresponse to initial antibiotics. This intriguing fact may be linked to changes in the phenotype of inflammatory cells and, in particular, to the induction of classical-M1 or alternative-M2 activation of macrophages, which result in different inflammatory profiles.We evaluated the effect of sputum obtained from patients with acute exacerbation of COPD (AECOPD), CAP and COPD+CAP on the phenotypic changes in macrophages. Human THP1 cells differentiated to macrophages were incubated with sputum from patients with AECOPD, CAP or COPD+CAP, and expression of tumour necrosis factor-alpha, interleukin-6, mannose receptor and arginase was measured to evaluate the phenotype acquired by macrophages. We found that sputum from CAP patients induced the M1 phenotype and that from AECOPD patients induced an M2-like phenotype. Sputum from CAP+COPD patients did not present a clear M1 or M2 phenotype.These results indicate that the microenvironment in the lung modulates the activation of macrophages, resulting in different phenotypes in AECOPD, CAP and COPD+CAP patients. This different type of activation induces different inflammatory responses and may be involved in the different outcome observed when COPD and CAP present simultaneously.